Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
The US Justice Department charged Israeli generic drug firm Teva for conspiring to price-fixing, rigging bids, and allocating customers for generic drugs between 2013 and 2015.
The alleged transgressions caused patients to overpay by over $350 million.
Among the generic drugs was the cholesterol-regulating Pravastatin.
Teva, which sold $17 billion worth of drugs last year, rejected the charges saying it was “deeply disappointed" that the government proceeded with the prosecution.
It added that the US was unwilling to consider alternatives that would not be as impactful.
Five companies investigated in the case, including Sandoz, Taro, and Apotex have already paid fines to avoid prosecution.
Sandoz paid $195 million in March, while Apotex agreed to a $24.1 million fine in May.
In July, the American subsidiary of Israel's Taro Pharmaceuticals paid $205.7 million.
Earlier this month, Teva was also accused of inflating the reimbursement price for its multiple sclerosis drug, Copaxone, for patients in the Medicare program.
